The Library

Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi

Tools

Bell, David J., Wootton, Daniel G., Mukaka, Mavuto, Montgomery, Jacqui, Kayange, Noel, Chimpeni, Phillips, Hughes, Dyfrig, Molyneux, Malcolm E., Ward, Steve A., Winstanley, Peter and Lalloo, David G.. (2009) Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malaria Journal, Vol.8 (No.204). ISSN 1475-2875

Preview

PDF
WRAP_Winstanley_1475-2875-8-204.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (325Kb)

Official URL: http://dx.doi.org/10.1186/1475-2875-8-204

Abstract

Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicated malaria, but there is widespread resistance. At the time of this study, artemether-lumefantrine (AL) and chlorproguanil-dapsone (CPD), both multi-dose regimes, were considered possible alternatives to SP in Malawi. The aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD.

Item Type:

Journal Article

Subjects:

R Medicine > RA Public aspects of medicine

Divisions:

Faculty of Medicine > Warwick Medical School

Library of Congress Subject Headings (LCSH):

Malaria -- Treatment -- Malawi

Journal or Publication Title:

Malaria Journal

Publisher:

BioMed Central Ltd.

ISSN:

1475-2875

Official Date:

29 August 2009

Dates:

Date	Event
29 August 2009	Published

Volume:

Vol.8

Number:

No.204

Identification Number:

10.1186/1475-2875-8-204

Status:

Peer Reviewed

Publication Status:

Published

Access rights to Published version:

Open Access

Funder:

Great Britain. Dept. for International Development

Grant number:

RES 8074 (DID)

References:

1. Sulo J, Chimpeni P, Hatcher J, Kublin JG, Plowe CV, Molyneux ME,
Marsh K, Taylor TE, Watkins WM, Winstanley PA: Chlorproguanildapsone
versus sulfadoxine-pyrimethamine for sequential
episodes of uncomplicated falciparum malaria in Kenya and
Malawi: a randomised clinical trial. Lancet 2002, 360:1136-1143.
2. Press Release on Lapdap [http://www.gsk.com/media/pressre
leases/2008/2008_pressrelease_0014.htm]
3. Assessment and monitoring of antimalarial drug efficacy for
the treatment of uncomplicated falciparum malaria [http://
www.who.int/malaria/docs/ProtocolWHO.pdf]
4. Lindegardh N, Annerberg A, Blessborn D, Bergqvist Y, Day N, White
NJ: Development and validation of a bioanalytical method
using automated solid-phase extraction and LC-UV for the
simultaneous determination of lumefantrine and its desbutyl
metabolite in plasma. J Pharm Biomed Anal 2005, 37:1081-1088.
5. Price RN, Uhlemann AC, van VM, Brockman A, Hutagalung R, Nair S,
Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten
F: Molecular and pharmacological determinants of the therapeutic
response to artemether-lumefantrine in multidrugresistant
Plasmodium falciparum malaria. Clin Infect Dis 2006,
42:1570-1577.
6. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, Sanandaji S, Christian
J, Maldonado T, Duran D, Kaplan AH, Wenger NS: A comparison
study of multiple measures of adherence to HIV protease
inhibitors. Ann Intern Med 2001, 134:968-977.
7. World Malaria Report 2008 [http://www.who.int/malaria/
wmr2008/]
8. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB: The concordance
of self-report with other measures of medication
adherence: a summary of the literature. Med Care 2004,
42:649-652.
9. Bell DJ, Kapitao Y, Sikwese R, van Oosterhout JJ, Lalloo DG: Adherence
to antiretroviral therapy in patients receiving free
treatment from a government hospital in Blantyre, Malawi.
J Acquir Immune Defic Syndr 2007, 45:560-563.
10. Rahman MM, Dondorp AM, Day NP, Lindegardh N, Imwong M, Faiz
MA, Bangali AM, Kamal AT, Karim J, Kaewkungwal J, Singhasivanon P:
Adherence and efficacy of supervised versus non-supervised
treatment with artemether/lumefantrine for the treatment
of uncomplicated Plasmodium falciparum malaria in Bangladesh:
a randomised controlled trial. Trans R Soc Trop Med Hyg
2008, 102:861-867.
11. Ajayi IO, Browne EN, Bateganya F, Yar D, Happi C, Falade CO,
Gbotosho GO, Yusuf B, Boateng S, Mugittu K, Cousens S, Nanyunja
M, Pagnoni F: Effectiveness of artemisinin-based combination
therapy used in the context of home management of
malaria: a report from three study sites in sub-Saharan
Africa. Malar J 2008, 7:190.
12. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, Namiiro P,
Musabe J, Kyomugisha A, Guthmann JP: Adherence to a six-dose
regimen of artemether-lumefantrine for treatment of
uncomplicated Plasmodium falciparum malaria in Uganda.
Am J Trop Med Hyg 2004, 71:525-530.
13. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J: Simplified
antimalarial therapeutic monitoring: using the day-7 drug
level? Trends Parasitol 2008, 24:159-163.
14. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC,
Kitcher ED, Badoe EV, Lamptey R, Goka BQ: Amodiaquineartesunate
vs artemether-lumefantrine for uncomplicated
malaria in Ghanaian children: a randomized efficacy and
safety trial with one year follow-up. Malar J 2008, 7:127.
15. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira
J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W,
Checchi F, Guthmann JP: Supervised versus unsupervised intake
of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara,
Uganda: a randomised trial. Lancet 2005, 365:1467-1473.
16. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, Maiga
H, Niambele MB, Sissoko M, Dicko A, Djimde A, Doumbo OK: A
randomized trial of artesunate-mefloquine versus artemether-
lumefantrine for treatment of uncomplicated Plasmodium
falciparum malaria in Mali. Am J Trop Med Hyg 2008,
79:655-661.
17. Urquhart J: Pharmacodynamics of variable patient compliance:
implications for pharmaceutical value. Adv Drug Deliv Rev
1998, 33:207-219.